Global Cancer Pain Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cancer Pain Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Cancer pain is one of the most common symptoms in cancer patients. Pain can be caused by cancer, cancer treatment, or a combination of factors.
Global Cancer Pain market is projected to reach US$ 8568 million in 2029, increasing from US$ 6198 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029. Demand from Radiotherapy and Chemotherapy are the major drivers for the industry.
The growth of the global cancer pain market is mainly due to the increasing prevalence of cancer; rising geriatric population; rising healthcare expenditure; and increasing investment in research and development activities by various healthcare companies. Due to aging effects and genetic mutations, older people are more prone to various types of cancer, such as lung cancer, bladder cancer, kidney cancer, melanoma, etc. According to the National Cancer Institute, the median age at diagnosis is 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer and 66 for prostate cancer. However, side effects associated with drugs used in cancer pain treatment, such as drug tolerance, drug dependence, urinary retention, sleep disturbance, cognitive impairment, etc., are expected to restrain the growth of the cancer pain market over the forecast period.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Pain market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Eli-Lilly
Grunenthal Group
GW Pharmaceuticals
Johnson＆Johnson
Meda Pharmaceuticals
Orexo
Sanofi
WEX Pharmaceuticals
Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Radiotherapy
Chemotherapy
Hormone Therapy
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cancer Pain market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cancer Pain introduction, etc. Cancer Pain Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Cancer Pain market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Global Cancer Pain market is projected to reach US$ 8568 million in 2029, increasing from US$ 6198 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029. Demand from Radiotherapy and Chemotherapy are the major drivers for the industry.
The growth of the global cancer pain market is mainly due to the increasing prevalence of cancer; rising geriatric population; rising healthcare expenditure; and increasing investment in research and development activities by various healthcare companies. Due to aging effects and genetic mutations, older people are more prone to various types of cancer, such as lung cancer, bladder cancer, kidney cancer, melanoma, etc. According to the National Cancer Institute, the median age at diagnosis is 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer and 66 for prostate cancer. However, side effects associated with drugs used in cancer pain treatment, such as drug tolerance, drug dependence, urinary retention, sleep disturbance, cognitive impairment, etc., are expected to restrain the growth of the cancer pain market over the forecast period.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Pain market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Eli-Lilly
Grunenthal Group
GW Pharmaceuticals
Johnson＆Johnson
Meda Pharmaceuticals
Orexo
Sanofi
WEX Pharmaceuticals
Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Segment by Application
Radiotherapy
Chemotherapy
Hormone Therapy
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cancer Pain market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cancer Pain introduction, etc. Cancer Pain Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Cancer Pain market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices